Dr. Sreekanth C. Reddy, MD

Dr. Reddy practices at Memorial Health Meadows Hospital in Vidalia, Georgia, part of HCA Healthcare.

Dr. Reddy's NPI, 1437199965, was assigned on June 6, 2006. Dr. Reddy holds Georgia license 49476.

Dr. Reddy's primary practice is Memorial Health Meadows Hospital, at One Meadows Parkway, Vidalia, GA 30474 in Toombs County. The practice phone is (912) 535-5828. Dr. Reddy also practices at Meadows Regional Medical Center, 1 Meadows Pkwy, Vidalia, GA 30474.

Dr. Reddy's primary practice is Memorial Health Meadows Hospital in Vidalia, Georgia, part of HCA Healthcare. Dr. Reddy is also affiliated with Northside Hospital Atlanta. The medical group on file is Zangmeister Cancer Center. Dmand AI also links Dr. Reddy to 3 more hospitals, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reddy practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Reddy's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Reddy is licensed in Georgia.

CMS data shows 135,075 Medicare services from Dr. Reddy across 58 procedure codes in 2024, for 707 Medicare patients. Medicare paid $3,229,432 for them. Every service was in an office.

CMS counts 707 Medicare patients who saw Dr. Reddy in 2024. The largest group is 75 to 84, with 298 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reddy's median patient age at 68, with 58% women.

In 2024, Dr. Reddy wrote 2,153 Medicare Part D claims for 414 patients. 67% of them were for generic drugs. CMS names the drug for 1,835 of them, across 49 drugs with 11 or more claims each, at $5,672,192 in total drug cost. In 2023, CMS named 1,587 claims across 49 drugs.

Dr. Reddy accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Reddy, published from 2019 to 2024. 2019 was the busiest year, with 2. The most frequent topics are Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Squamous Cell. Dr. Reddy's most frequent co-authors are Davey B. Daniel, MD, David Raymond Gandara, MD and Lowell L. Hart, MD.

Dmand AI links Dr. Reddy to 10 clinical trials, 5 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 997 general payments to Dr. Reddy from 85 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 44% of the total. Medtronic USA, Inc. paid the most, $19,948.